Personalized Treatment of Breast Cancer

Masakazu Toi, Professor, Breast Surgery, Kyoto UniversityEric P Winer, Professor, Department of Medicine, Harvard Medical School John R Benson, Professor, Cambridge Breast Unit, Cambridge University Suzanne Klimberg, Breast Surgical Oncology, University of Arkansas for Medical Sciences.

• Part I Treatment for the Patients Having Breast Cancer High-Risk.- Chapter I Risk-Reducing Surgery for Breast Cancer Patients with BRCA Mutations.- Chapter 2 Prophylactic Risk Reducing Surgery for Breast Cancer.- Chapter 3 Merits and Demerits of Practice for Hereditary Breast and Ovarian Cancer Syndrome (Advices and Issues).- Part II Axillary Treatment.- Chapter 4 Sentinel Lymph Node Biopsy and Neoadjuvant Chemotherapy in Breast Cancer Patients.- Chapter 5 Axillary Reverse Mapping (ARM) as a Means to Reduce Lymphedema During Sentinel Lymph Node or Axillary Node Dissection.- Chapter 6 Ultrasound for Axillary Staging.- Chapter 7 One Step Nucleic Acid Amplification(OSNA)Assay for Primary Breast Cancer.- Chapter 8 Management of the Clinically Node-Negative Axilla in Primary Breast Cancer.- Chapter 9 Lymphatic Mapping and Optimization of Sentinel Lymph Node Dissection.- Part III Radiation therapy.- Chapter 10 Personalization ofRadiotherapy for Breast Cancer.- Chapter 11 New Technologies in Radiation Therapy.- Chapter 12 Radiotherapy Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.- Part IV Preoperative Hormone Therapy.- Chapter 13 Novel Translational Research of Neoadjuvant Endocrine Therapy.- Chapter 14 Alterations of Biomarkers by Neoadjuvant Endocrine Therapy.- Part V Preoperative chemotherapy.- Chapter 15 Essence of Neoadjuvant Therapy.- Chapter 16 The challenge to Overcome Triple Negative Breast Cancer Heterogeneity.- Chapter 17 Surgical Management of Breast Cancer after Preoperative Systemic Treatment.- Chapter 18 Imaging of Tumor Response by Preoperative Systemic Treatment.- Part VI Preoperative anti-HER2 therapy.- Chapter 19 Human Epidermal Growth Factor Receptor (HER) Family Molecular Structure.- Chapter 20 Locoregional Therapy Following Neoadjuvant Therapy for HER2-Positive Breast Cancer: Opportunities and Challenges.- Part VII Mathematical prediction/assessment model.- Chapter 21 Nomograms to predict positive resection margin and to predict 3 or more positive lymph nodes.- Chapter 22 Practical Use of Nomograms.- Chapter 23 Data Mining and Mathematical Model Development.

“The intended audience is young physicians who should learn the scientific foundations of personalization, as well as current practitioners who wish to access recent information. As with many multiauthored specialized books, this one is best thought of as a series of reviews of selected topics. Thus, some topics will be of value to junior physicians and others to more senior ones. The authors are all highly credible authorities from either Japan or the U.S.” (Carol Scott-Conner, Doody's Book Reviews, August, 2016)